[HTML][HTML] EGFR-TKIs plus bevacizumab demonstrated survival benefit than EGFR-TKIs alone in patients with EGFR-mutant NSCLC and multiple brain metastases
T Jiang, Y Zhang, X Li, C Zhao, X Chen, C Su… - European Journal of …, 2019 - Elsevier
Introduction Previous studies suggested that epidermal growth factor receptor (EGFR)–
tyrosine kinase inhibitor (TKIs) plus bevacizumab could significantly prolong progression …
tyrosine kinase inhibitor (TKIs) plus bevacizumab could significantly prolong progression …
Combination therapy of brain radiotherapy and EGFR-TKIs is more effective than TKIs alone for EGFR-mutant lung adenocarcinoma patients with asymptomatic brain …
Y Chen, J Wei, J Cai, A Liu - BMC cancer, 2019 - Springer
Background The treatment strategy for brain metastasis (BM) in patients with epidermal
growth factor receptor (EGFR)-mutant lung adenocarcinoma (LAC) remains controversial. In …
growth factor receptor (EGFR)-mutant lung adenocarcinoma (LAC) remains controversial. In …
A phase II study of Osimertinib for patients with radiotherapy-naïve CNS metastasis of non-small cell lung cancer: treatment rationale and protocol design of the …
K Wakuda, H Yamaguchi, H Kenmotsu, M Fukuda… - BMC cancer, 2020 - Springer
Background Patients with activating epidermal growth factor receptor (EGFR) mutations are
highly responsive to EGFR-tyrosine kinase inhibitors (TKIs). However, it has been reported …
highly responsive to EGFR-tyrosine kinase inhibitors (TKIs). However, it has been reported …
Role of EGFR inhibitors in the treatment of central nervous system metastases from non-small cell lung cancer
GL Ceresoli - Current Cancer Drug Targets, 2012 - ingentaconnect.com
Brain metastases (BM) are a common occurrence in patients with non-small cell lung cancer
(NSCLC). Standard therapy options include whole brain radiotherapy and, in selected …
(NSCLC). Standard therapy options include whole brain radiotherapy and, in selected …
The Impact of Initial Gefitinib or Erlotinib versus Chemotherapy on Central Nervous System Progression in Advanced Non–Small Cell Lung Cancer with EGFR …
S Heon, BY Yeap, NI Lindeman, VA Joshi… - Clinical Cancer …, 2012 - AACR
Purpose: This retrospective study was undertaken to investigate the impact of initial gefitinib
or erlotinib (EGFR tyrosine kinase inhibitor, EGFR-TKI) versus chemotherapy on the risk of …
or erlotinib (EGFR tyrosine kinase inhibitor, EGFR-TKI) versus chemotherapy on the risk of …
Efficacy of EGFR‐TKIs with or without upfront brain radiotherapy for EGFR‐mutant NSCLC patients with central nervous system metastases
Y Saida, S Watanabe, T Abe, S Shoji, K Nozaki… - Thoracic …, 2019 - Wiley Online Library
Background Although the clinical efficacy of epidermal growth factor receptor tyrosine kinase
inhibitors (EGFR‐TKIs) in EGFR‐mutant non‐small cell lung cancer (NSCLC) patients has …
inhibitors (EGFR‐TKIs) in EGFR‐mutant non‐small cell lung cancer (NSCLC) patients has …
Overall survival benefit of osimertinib and clinical value of upfront cranial local therapy in untreated EGFR‐mutant nonsmall cell lung cancer with brain metastasis
Y Zhao, S Li, X Yang, L Chu, S Wang… - … journal of cancer, 2022 - Wiley Online Library
Osimertinib, as a third‐generation epidermal growth factor receptor (EGFR) tyrosine kinase
inhibitor (TKI), showed more potent efficacy against brain metastasis (BM) in untreated …
inhibitor (TKI), showed more potent efficacy against brain metastasis (BM) in untreated …
Osimertinib plus local treatment for brain metastases versus osimertinib alone in patients with EGFR-Mutant Non-Small Cell Lung Cancer
T Tozuka, R Noro, H Mizutani, F Kurimoto, T Hakozaki… - Lung Cancer, 2024 - Elsevier
Objectives Osimertinib is a standard treatment for patients with EGFR-mutant non-small cell
lung cancer (NSCLC) and is highly effective for brain metastases (BMs). However, it is …
lung cancer (NSCLC) and is highly effective for brain metastases (BMs). However, it is …
[HTML][HTML] Brain metastases in EGFR-positive non-small cell lung cancer: the way to the sanctuary becomes less winding
A Passaro, L Gianoncelli, V Stati… - Annals of Translational …, 2019 - ncbi.nlm.nih.gov
In every day clinical practice, we find ourselves having to face the age-old problem of brain
metastases (BM) in nonsmall cell lung cancer (NSCLC) patients. Despite the high incidence …
metastases (BM) in nonsmall cell lung cancer (NSCLC) patients. Despite the high incidence …
Optimal sequence of LT for symptomatic BM in EGFR-mutant NSCLC: a comparative study of first-line EGFR-TKIs with/without upfront LT
L Niu, H Wu, R Gao, L Chen, J Wang, H Duan… - Journal of Cancer …, 2024 - Springer
Background The third-generation epidermal growth factor receptor tyrosine kinase inhibitors
(EGFR-TKIs) can penetrate blood–brain barrier and are effective for brain metastases (BMs) …
(EGFR-TKIs) can penetrate blood–brain barrier and are effective for brain metastases (BMs) …